Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma
- 6 January 2015
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 170 (1), 131-134
- https://doi.org/10.1111/bjh.13275
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosisLeukemia Research, 2013
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)Leukemia & Lymphoma, 2013
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesJournal of Clinical Oncology, 2013
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2012
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- B Cell Antigen Receptor Signaling: Roles in Cell Development and DiseaseScience, 2002